SEATTLE, Aug. 06, 2018 — Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to dilanubicel (NLA101) for patients with high-risk hematologic malignancies receiving an allogeneic cord blood transplant. Dilanubicel has already received PRIME designation from the European Medicines Agency, and Orphan Drug Designation from the FDA and European Commission. [Read more…]
Nohla Therapeutics Secures $45 Million to Develop Cord Blood Treatment for Leukemia
Nohla Therapeutics Announces Closing of $45 Million Series B Financing
Proceeds to Support the Development of Dilanubicel (NLA101) and Additional Platform Programs
Seattle, WA; May 15, 2018 – Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases, today announced the closing of a $45 million Series B financing. In this round, Fidelity Management and Research Company and Celgene Corporation (Nasdaq: CELG) joined existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners, who also participated in the financing. [Read more…]
Nohla Therapeutics Investors Provide $43.5M for Universal Donor Stem Cell Therapies
Seattle, Washington – Nohla Therapeutics Inc. (Nohla), a biotechnology company pioneering the field of universal donor cellular therapies for treating patients with life threatening hematological disorders and cancers, today announced the initial closing of a $43.5M Series A financing round. [Read more…]
Nohla Therapeutics to Acquire Clinical Grade Cord Blood Units from LifeSouth for Expanded HSC Products
Nohla Therapeutics has signed an exclusive supply agreement with LifeSouth Community Blood Centers headquartered in Gainesville, Florida. Under this agreement, LifeSouth’s cord blood banking program will supply Nohla Therapeutics with clinical grade cord blood units that will be used in the production process for the Company’s expanded hematopoietic stem and progenitor cell (HSC/HPC) products. [Read more…]
Nohla Therapeutics Launches with Major US Cancer Research Institute Deal, Substantial Investment Round, and Key Appointments
Nohla Therapeutics Inc.
Benjamin Bergo, +1 206 310 5560 (US)
Nohla Therapeutics Inc.
Michael Sistenich, +61 (0)413 087 194 (AUS)
Head of Corporate Development
Ben Walsh, +61 (0)468 422 865 (AUS)
Ben Navon, +1 (617) 234-4104 (US)
Want to be better informed than your competition? Get future stem cell industry updates.
BioInformant is the first and only market research firm to specialize exclusively in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, CBS News, Medical Ethics, and the Center for BioNetworking. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.
Click here to view our global strategic reports for the stem cell and cord blood industry.